Evidence map›Paper›PMID 28326542›Full record

ReviewBritish journal of pharmacology2017

Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Fatima Iqbal, Wendy S Baker, Madiha I Khan, Shwetha Thukuntla, Kevin H McKinney, Nicola Abate, Demidmaa Tuvdendorj

Abstract readReview
In one paragraph

Review in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Hot Water Extract ofNutrients · 2019
    Trial
  3. Trial
  4. Article
  5. Foods (Basel, Switzerland) · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Association ofJGH open : an open access journal of gastroenterology and hepatology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Sex-dependent difference in the relationship between adipose-tissue cholesterol efflux and estradiol concentrations in young healthy humans.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatima IqbalDivision of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Wendy S BakerDivision of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Madiha I KhanDivision of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Shwetha ThukuntlaDivision of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Kevin H McKinneyDivision of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Nicola AbateDivision of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Demidmaa TuvdendorjDivision of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
UTMB OAIC Research Education Component (REC)P30AG024832 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI JAMES S. GOODWIN, MD, MELISSA M. MORROW · 2005 to 2026
$26.7M
UTMB CLINICAL AND TRANSLATIONAL SCIENCE AWARD: NASA BED REST STUDIESUL1RR029876 · NCRR · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2009 to 2011
$17.7M
UTMB Clinical and Translational Science AwardUL1TR000071 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$14.4M
UTMB Clinical and Translational Science AwardKL2TR001441 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI AMEREDES, BILL T · 2015 to 2024
$4.0M
UTMB Clinical and Translational Science AwardKL2RR029875 · NCRR · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2009 to 2011
$609k
UTMB Clinical and Translational Science AwardKL2TR000072 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$422k
NCATS NIH HHS KL2 TR000072NCATS NIH HHS KL2 TR001441NCATS NIH HHS UL1 TR000071NCATS NIH HHS UL1 TR001439NCRR NIH HHS KL2 RR029875NCRR NIH HHS UL1 RR029876NIA NIH HHS P30 AG024832
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Inflammatory processes arising from metabolic abnormalities are known to precipitate the development of CVD. Several metabolic and inflammatory markers have been proposed for predicting the progression of CVD, including high density lipoprotein cholesterol (HDL-C). For ~50 years, HDL-C has been considered as the atheroprotective 'good' cholesterol because of its strong inverse association with the progression of CVD. Thus, interventions to increase the concentration of HDL-C have been successfully tested in animals; however, clinical trials were unable to confirm the cardiovascular benefits of pharmaceutical interventions aimed at increasing HDL-C levels. Based on these data, the significance of HDL-C in the prevention of CVD has been called into question. Fundamental in vitro and animal studies suggest that HDL-C functionality, rather than HDL-C concentration, is important for the CVD-preventive qualities of HDL-C. Our current review of the literature positively demonstrates the negative impact of systemic and tissue (i.e. adipose tissue) inflammation in the healthy metabolism and function of HDL-C. Our survey indicates that HDL-C may be a good marker of adipose tissue health, independently of its atheroprotective associations. We summarize the current findings on the use of anti-inflammatory drugs to either prevent HDL-C clearance or improve the function and production of HDL-C particles. It is evident that the therapeutic agents currently available may not provide the optimal strategy for altering HDL-C metabolism and function, and thus, further research is required to supplement this mechanistic approach for preventing the progression of CVD. LINKED ARTICLES: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.

Indexed as

AnimalsAnti-Inflammatory AgentsCholesterol, HDLHumansInflammationLipid MetabolismAnti-Inflammatory AgentsCholesterol, HDL

Identifiers

PMID28326542
PMCPMC5660004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.